bamzireotide bamzireotide navoxetan Updated Nov 9
Watch for the End-of-Phase 2 meeting outcome with the FDA in Q1 2027, which will determine the Phase 3 trial design and registration path. Positive FDA alignment could re-rate the stock from its deeply depressed levels, while negative feedback or a delayed timeline would add to the execution risks flagged by RBC. The company's ~$100M market cap and likely need for financing to fund a Phase 3 trial create additional overhang.
- Phase 1/2a data showed a 39% objective response rate and 75% 18-month PFS in 57 GEP-NET patients, comparing favorably to the approved beta-emitter Lutathera (roughly 13% ORR per the company's comparison).
- Cohort 3 (24 mCi dose) showed a 47% ORR and 100% disease control rate, suggesting a dose-response relationship.
- Clean safety profile across 68 patients: no dose-limiting toxicities, no treatment-related discontinuations, no Grade 4/5 adverse events.
- Phase 1/2a data come from a small, non-randomized study (n=57 for efficacy); results may not replicate in a larger Phase 3 trial.
- RBC Capital downgraded the stock to Sector Perform from Outperform on October 26, 2026, cutting its price target from $14 to $4, citing execution risks around bamzireotide's competitive market, future Phase 3 conduct, and manufacturing build-out.
- Major insider Lantheus (a 10%+ owner) sold roughly 500,000 shares in late August/early September 2026 at ~$3.10 per share.